Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 3/20 | 0.58 |
| ▸ | JAK1 | P23458 | 9/20 | 0.56 |
| ▸ | JAK2 | O60674 | 5/20 | 0.56 |
| ▸ | JAK3 | P52333 | 2/20 | 0.56 |
| ▸ | TYK2 | P29597 | 1/20 | 0.56 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.52 |
| ▸ | CKS1B | P61024 | 1/20 | 0.50 |
| ▸ | SKP1 | P63208 | 1/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.45 |
| ▸ | ATR | Q13535 | 2/20 | 0.44 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24600565 | 0.85 | CKS1B (0.48) | AKT2JAK1JAK2JAK3TYK2 | |
| SCHEMBL29691572 | 0.85 | CKS1B (0.48) | AKT2JAK1JAK2JAK3TYK2 | |
| SCHEMBL30151464 | 0.85 | KIT (0.60) | AKT2JAK1JAK2JAK3TYK2 | |
| SCHEMBL1005506 | 0.85 | KIT (0.60) | AKT2JAK1JAK2JAK3TYK2 | |
| SCHEMBL15443939 | 0.84 | JAK1 (0.54) | JAK1JAK2JAK3TYK2PBK | |
| SCHEMBL20647989 | 0.82 | CKS1B (0.48) | JAK1JAK2JAK3TYK2CKS1B | |
| SCHEMBL15169781 | 0.81 | JAK3 (0.57) | JAK1JAK2JAK3 | |
| SCHEMBL10074324 | 0.81 | JAK3 (0.57) | JAK1JAK2JAK3 | |
| SCHEMBL20641158 | 0.81 | MAP3K5 (0.58) | JAK1JAK2JAK3CKS1BSKP1 | |
| SCHEMBL21173533 | 0.81 | CKS1B (0.56) | JAK1JAK2CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3719018-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2025-08-27 | — | — | EP | disclosed |
| US-20220169653-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2022-06-02 | — | — | US | disclosed |
| US-20220169653-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2022-06-02 | — | — | US | disclosed |
| US-11136325-B2 | Pyrrolopyrimidine and pyrrolopyridine derivatives | GALAPAGOS NV (BE) | 2021-10-05 | — | — | US | disclosed |
| US-11136325-B2 | Pyrrolopyrimidine and pyrrolopyridine derivatives | GALAPAGOS NV (BE) | 2021-10-05 | — | — | US | disclosed |
| EP-3421471-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2021-05-26 | — | — | EP | disclosed |
| EP-3421471-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2021-05-26 | — | — | EP | disclosed |
| EP-3719018-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Ltd (GB) | 2020-10-07 | — | — | EP | disclosed |
| EP-3719018-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Ltd (GB) | 2020-10-07 | — | — | EP | disclosed |
| US-20200165259-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2020-05-28 | — | — | US | disclosed |
| US-8796293-B2 | Purine and deazapurine derivatives as pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| US-20140107137-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-04-17 | — | — | US | disclosed |
| US-20140107137-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-04-17 | — | — | US | disclosed |
| US-8546407-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2013-10-01 | — | — | US | disclosed |
| US-8546407-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2013-10-01 | — | — | US | disclosed |
| EP-1812004-B1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2011-06-22 | — | — | EP | disclosed |
| EP-2272517-A1 | Ortho-condensed pyridine and pyrimidine derivatives ( e.g. purines ) as protein kinases inhibitors | Astex Therapeutics Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| US-20100022564-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2009-10-01 | — | — | US | disclosed |
| WO-2007125321-A2 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165259-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | IRAK1, PEAK1, MARK1 | AKT2 2675/4885JAK1 40/4885JAK2 211/4885 |
| US-20140107137-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CDK1, CDK2, CDK3 | AKT2 630/4885JAK1 372/4885JAK2 426/4885 |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CDK2, CDK1, OXSR1 | AKT2 496/4885JAK1 357/4885JAK2 391/4885 |
| US-11136325-B2 | Pyrrolopyrimidine and pyrrolopyridine derivatives | IRAK1, PEAK1, MARK1 | AKT2 2675/4885JAK1 40/4885JAK2 211/4885 |
| US-20220169653-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | IRAK1, PEAK1, MARK1 | AKT2 2675/4885JAK1 40/4885JAK2 211/4885 |
| US-20100022564-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | TPMT, CNKSR1, PRKD3 | AKT2 126/4885JAK1 149/4885JAK2 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.